Sanofi
corporate_fare Company Profile
Sanofi (NASDAQ:SNY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 48 items for SNY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 16 rated 8 or above. Recent SEC coverage for SNY spans 6-K.
Recent high-impact activity:
- Sanofi Wins FDA Nod for First Oral Gaucher Therapy, EU Approval for New Rabies Shot
- Sanofi Beats Q3, Lifts 2026 Outlook as Dupixent Tops €5.7B
- Sanofi Pays Up to $8B to Expand Regeneron Alliance With Four Long-Acting Drugs
- Sanofi Divests 20 Mature Medicines and 3 Plants to Cheplapharm for 26.4% Equity Stake
- Sanofi's MenQuadfi Wins EU Nod for Infants, Broadening Its Meningococcal Vaccine Reach
Financial Snapshot
Short Interest & Short Volume
2.85 days to coverFINRA reported short interest of 12,291,525 shares in SNY as of the October 30, 2026 settlement, a 5.9% increase from the prior period — about 2.9 days to cover at its recent average daily volume. On November 20, 2026, 20.5% of SNY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
SNY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.